Biotechnology

Wednesday Dec 22, 2021 - 12:37 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Complete Initial Shipment of sugarBEAT(R) Devices to UK Licensee

Nemaura Medical announced the successful completion of its initial shipment of sugarBEAT(R) continuous glucose monitor devices to its UK licenseeThe initial shipment, which comprised 5,000 CGM devices and 200,000 sensors, is expected to result in follow-on monthly orders of up to 2 million sensors and 15,000 CGM devices over the next two yearsFollowing the launch of the sugarBeat(R), Nemaura Medical have released the MiBoKo application,…

Monday Dec 20, 2021 - 12:11 pm

RYAH Group Inc. (CSE: RYAH) Releases Medical Cannabis Report on Cancer and Adverse Cancer Treatment Effects

RYAH recently released report highlighting medical cannabis treatment for cancer and adverse effects of cancer treatmentData from 80,000 sessions logged between January 1, 2018 and November 15, 2021 tracked conditions including anxiety, cachexia, fatigue, pain, nausea, and stress62% of patients reported a moderate experience using cannabis to treat cancer-related conditionsRYAH supports cancer research and treatment with IoT product ecosystem comprised of volume-control devices, medicine-carrying components,…

Monday Dec 20, 2021 - 11:50 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment

Mydecine’s and CMPS’ stocks have been grossly undervalued largely due to a lack of understanding of the psychedelic space The situation presents a unique opportunity for investment, as Roth Capital Partners issued a $3 buy rating for 2022Mydecine has put systems and infrastructure in place to bank on the growing PTSD treatment, smoking cessation, and the health and wellness apps market, in its drive to increase…

Friday Dec 10, 2021 - 1:16 pm

Don’t Miss NCIA’s 7th Annual Cannabis Business Summit & Expo

Date: December 15-17, 2021 Venue: Moscone Center, San Francisco, California NCIA’s 7th Annual Cannabis Business Summit & Expo will be held in the Moscone Center in San Francisco, California, on December 15-17, 2021. Hosted by the National Cannabis Industry Association ("NCIA"), the largest and oldest national trade association advancing the interests of the legal cannabis industry, the three-day event showcases cannabis industry professionals and advocates…

Friday Dec 10, 2021 - 12:56 pm

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Discusses Psychedelics Research, Life Sciences Focus, at Key Industry Conferences

MINDCURE President and CEO Kelsey Ramsden will participate in, and has already attended multiple industry conferences throughout DecemberParticipation in #CanndoraConnect: Women in Psychedelics Conference focused on exploring job opportunities in psychedelicsCompany remains focused on promoting healing and improving mental health via digital therapeutics technology and psychedelic compounds researchCompany reports that 971 million people worldwide suffer from a mental disorder. As of 2019, MINDCURE calculates that…

Friday Dec 10, 2021 - 9:31 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin

The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybinIn addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nauseaMydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing…

Thursday Dec 09, 2021 - 1:35 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp just announced FDA confirmation for its IND application filed in November 2021The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgiaThis clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 studyIt is set to commence in 2022 and will involve 20 fibromyalgia patients…

Thursday Dec 09, 2021 - 1:24 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital

Company receives grant to fund clinic for marginalized, underserved NYC communitiesNew clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the serviceProgram’s clinicians will receive specialized training Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the…

Tuesday Dec 07, 2021 - 9:00 am

RYAH Group Inc. (CSE: RYAH) to Deliver Solutions for Clinicians Examining Cannabis Efficacy in Cancer Treatment

Multiple ongoing studies are researching the relationship between medical cannabis and cancer treatmentThe viability of clinical studies within the sector is hampered by lack of exact measurement of a patient’s intakeRYAH Group intends to resolve this issue with the launch of it’s proprietary RYAH Smart Dry Herb InhalerThe company successfully delivered on its first Inhaler order in May 2021, and announced that they had received…

Tuesday Dec 07, 2021 - 8:31 am

Nemaura Medical Inc. (NASDAQ: NMRD) Helping Diabetic Individuals Safeguard Themselves From COVID-19

1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the diseaseAs many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passingNemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devicesIn addition to sugarBEAT, its flagship device,…

Monday Dec 06, 2021 - 10:46 am

FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process

Pharmaceutical company Tryp Therapeutics is advancing research into the ability to treat unmet medical needs by using synthetic psychedelic drug candidates generally regarded as illegal and of no practical value under federal drug standardsThe company is demonstrating its faith in the potential of psychedelic medicine by advancing its proprietary TRP-8802 psilocybin candidate toward Phase 2a drug trials through the FDA’s Investigational New Drug processThe FDA…

Friday Dec 03, 2021 - 9:30 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Research and Technology Progress, Offers Corporate Update

Investment banking firm The Maxim Group reiterates ‘buy’ rating on MCURF following the company’s updates on pivotal research and technology, including The Desire Project, manufacturing of synthetic ibogaine, and the iSTRYM platformMINDCURE is focused on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwideIn July, MINDCURE filed for patents on two routes of full chemical synthesis, which initiated the production of Good…

Thursday Dec 02, 2021 - 9:30 am

Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited

NMRD releases fiscal Q2-2021 results, provides business updateHighlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory boardCompany operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable…

Thursday Dec 02, 2021 - 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Touts Highlights of ‘Transformative’ Second-Quarter Performance

Report notes significant and swift advancements in company R&D pipeline and overall businessPreliminary data indicates CYB003 may provide significant treatment benefits that address limitations of oral psilocybinCYBN programs and new psychedelic chemical entities have potential to transform treatment landscape for various psychiatric and neurological conditions Q2 2021 has been a transformative quarter for Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics…

Wednesday Dec 01, 2021 - 9:30 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Releases Q3 Update, Details JHU Five-Year Research Agreement

Mydecine’s recent Q3 update includes the company’s five-year research agreement with Johns Hopkins University School of Medicine, which will cover clinical research related to the therapeutic use of psychedelicsMydecine has also filed for various patents on proprietary compounds within the company’s IP portfolioIn addition, an updated version of the company’s virtual health platform, Mindleap 2.0, was released in Q3, enhancing user experience, infrastructure improvement, and…

Tuesday Nov 30, 2021 - 9:30 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Divisional Update Highlights Consistent Program and Product Progress Across the Board

MINDCURE plans to schedule a pre-IND meeting with the FDA for its Desire Project during Q1 2022 with a subsequent Phase 2 trial to begin Q3 2022The company expects that the GLP supply of ibogaine will be available for distribution to research partners in Q2 2022Information on MC-106 and MC-808, an expansion of MINDCURE’s drug pipeline, will be released during Q2 2022 As a member…

Monday Nov 29, 2021 - 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psilocybin Drug Program for the Treatment of Pain and Eating Disorders Takes On Special Meaning Leading Up To The Holidays

People with eating disorders know all about the difficulties faced during holiday celebrations and their association with heavy eatingThe fall-winter holiday season can also adversely affect people suffering from certain chronic pains, as temperatures and pressure changes can increase pain sensitivityTryp is looking to help alleviate problems associated with eating disorders and chronic pain through its psilocybin-based drug program that focuses on conditions with high…

Monday Nov 29, 2021 - 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs

InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trialsThe company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 millionFollowing the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare…

Monday Nov 22, 2021 - 8:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Excited for Seamless Phase 2/3 Clinical Research as Dr. Matthew Johnson Presents Interim Results of Current Smoking Cessation Study at the Psychedelic Medicine Business Event: Wonderland

Dr. Matthew Johnson discussed psilocybin for tobacco smoking cessation at this year’s Psychedelic Medicine Business Event: Wonderland, in MiamiHe shared preliminary findings from his recent study on substance use disorder, along with the participants’ feedback on their experienceDr. Johnson, along with Mydecine, are set to embark on their clinical study utilizing MYCO-001 for smoking cessation, set to commence in early 2022, building on the success…

Friday Nov 19, 2021 - 8:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health

Company releases positive results from preclinical study focusing on psilocybin program CYB003Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcareResults indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from…

Thursday Nov 18, 2021 - 8:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Offers ‘First-of-a-Kind’ Device in Growing CGM Market

The global continuous glucose monitoring devices market size is expected to reach $19.04 billion in 2028The increasing prevalence of diabetes, rising focus on preventive care are significant factors in the steady revenue growthNemaura Medical’s sugarBEAT device allows individuals to make adjustments to diet and activity that can significantly change their lives According to a recent Reports and Data release, the global consumer monitoring (“CGM”) devices global market…

Monday Nov 15, 2021 - 8:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Files Technology Patent Application Covering Bioavailability-Enhancing, Nanoemulsion-Empowered Formulations

Mydecine has filed a technology patent application that allows for the creation of nanoemulsion-empowered formulations to improve, stabilize, and increase the bioavailability of ingredientsThe company aims to use the nanoemulsion technology to enhance the bioavailability and optimize the delivery of compounds that are inspired by traditional ingredientsIn September, Mydecine filed its final patent application for MYCO-003, one of its lead drug candidates for enhanced treatment…

Friday Nov 12, 2021 - 12:23 pm

Recent Sector News Reveals Positive Data in Psychedelic Treatments For Depression as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Nears Launch of Synthetic Psilocybin Trials

Pharmaceutical company Tryp Therapeutics is developing a proprietary synthetic hallucinogen as potential medical solutions for select unmet health needs, with a focus on taking psychedelic therapeutics beyond mental healthThe company recently attended the Wonderland: Miami where Compass Pathways unveiled highly anticipated data from their Phase 2b trial in treatment-resistant depressionTryp’s Chairman and CEO Greg McKee served on a panel at Wonderland: Miami discussing the potential…

Thursday Nov 11, 2021 - 12:30 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Transformative Training Program for Psychedelic Facilitators

The EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experiencedProgram offers psychedelic clinical trial facilitators foundational training to provide skillful, ethical care to participants receiving psychedelic treatmentEMBARK is built around open architecture to support varieties of psychedelic experience within a coherent therapeutic framework In a climate where psychedelic treatments are increasing in usage and acceptance, the importance of providing…

Wednesday Nov 10, 2021 - 11:51 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid

InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative disease and potentially enhance the neuronal functionWith neurogenerative diseases affecting millions worldwide and the cost of treating patients expected to rise in the future, finding treatments and cures is a matter of increasing urgencyInMed’s patent application is a promising start, expanding the company’s…

Friday Nov 05, 2021 - 10:41 am

German Cannabis Market Expected to Liberalize Post Election, RYAH Group Inc. (CSE: RYAH) Enters Germany Via Observational Study

German Social Democrat-led coalition expected to liberalize medical cannabis market Analysts predict over one million medical cannabis patients in Germany by 2024, market estimated to reach $8.9 billion by 2028RYAH entered German market via observational study with Four 20 Pharma GmbHRYAH provides IoT product ecosystem of volume-control devices, medicine-carrying components, mobile applicationsRYAH ecosystem offers reliable way for researchers and clinicians to develop well-controlled research environments Germany’s…

Thursday Nov 04, 2021 - 12:48 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Marks Another Significant Milestone with IND Application for Fibromyalgia Phase 2a Clinical Trial

Tryp just filed an IND with the FDA for its TRP-8802 clinical candidate for its Phase 2a clinical trialThe trial is set to commence in 2022, subject to a favorable review by the FDAThe study will be conducted in collaboration with the University of Michigan and will aim at evaluating the safety and clinical utility of psilocybin for fibromyalgia Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF)…

Thursday Nov 04, 2021 - 12:12 pm

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution

The distribution component unlocks a new revenue source for the company, helping drive future growthMINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and painDigital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021 at a CAGR of 31.4 %, a substantial…

Monday Nov 01, 2021 - 1:18 pm

Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production

Special purpose acquisition company Soaring Eagle Acquisition Corp. combined with Ginkgo Bioworks to form publicly listed Ginkgo Bioworks Holdings Inc., in what is the largest-ever biotechnology go-public transactionGinkgo Bioworks is known for its work in the commercial-scale production of a rare cannabinoid, CBG, for use in a multitude of industrial needsInMed uses multiple manufacturing approaches to synthetically produce rare cannabinoids, including CBC which is currently…

Friday Oct 29, 2021 - 11:43 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Transforming Treatment of Fibromyalgia and Chronic Pain Conditions

In July, Tryp appointed Dr. Robin Carhart-Harris as the Chairman of its Scientific Advisory Board and Dr. Daniel Clauw, M.D., as a memberCommenting on the appointments, Tryp Chairman and CEO Greg McKee expressed his appreciation at the pair’s commitment to the alleviation of chronic pain and other diseases with psychedelic-based therapies as well as the companyFibromyalgia affects millions globally, but existing approved treatments have limited…

Wednesday Oct 27, 2021 - 9:30 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Is ‘One to Watch’

The Mydecine Innovations Group portfolio includes a robust portfolio of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates, as well as digital health solutionsThrough an exclusive partnership with Applied Pharmaceutical Innovations, the company has access to a Health Canada Scheduled 1 Drugs and Substances Dealer’s LicenseMydecine has a five-year master collaboration research agreement with…

Tuesday Oct 26, 2021 - 9:40 am

Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) Target Diabetes Tech

The world’s largest and most powerful tech companies –Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) – are targeting an opportunity in health care that’s just too big to ignore – diabetes. Almost a third of the entire U.S. population – more than 100 million people in this country alone – are living with diabetes or are at high risk for the disease.…

Thursday Oct 21, 2021 - 12:26 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announced Inclusion in AdvisorShares Psychedelics ETF; KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

Tryp announced its inclusion in the AdvisorShares Psychedelics ETFThe company hopes that its participation will open it up to a more diverse shareholder base and broaden its life science exposure Tryp’s presentation at the KCSA Virtual Investor Conference will also be available for on-demand viewing over the next 90 days Launched back in September 2021, the AdvisorShares Psychedelics Exchange-Traded Fund (“ETF”) has been actively trading, focusing…

Wednesday Oct 20, 2021 - 1:40 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine

Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicineCybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalationThe company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications Earlier this month, a Time magazine article reported on the “new era”…

Tuesday Oct 12, 2021 - 1:21 pm

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Among Leading Biotech Companies Innovating the Field of Early Cancer Screening and Detection

Blood and genomic testing are becoming preferable means of early cancer screening and detectionLeaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and GuardantAnPac Bio-Medical's testing features a database of more than 200,000 commercial and research multi-cancer test samples (probably the largest multi-cancer test data base) that detect up to 26 different types of cancerOne of the few companies offering multi-cancer…

Friday Oct 08, 2021 - 1:48 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Launch of New Website and Resources

Tryp Therapeutics recently launched a new website with updated resources to be featured on the siteOver the next few weeks, the company will share key resources that will be the standout features of the new websiteTryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities to existing investors and bring in more individuals who share in its…

Friday Oct 08, 2021 - 11:36 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces New Executives, Internal Promotions

Cybin names Dr. Amir Inamdar as chief medical officer for European operationsThe company appoints Dr. Geoff Varty as head of research and developmentBoth professionals bring decades of expertise to their new roles as Cybin focuses on progressing psychedelic therapeutics As Cybin (NEO: CYBN) (NYSE American: CYBN) continues its commitment to focus on the psychedelic therapeutic space and deliver proprietary drug-discovery platforms, the company has made…

Tuesday Oct 05, 2021 - 12:58 pm

RYAH Group Inc. (CSE: RYAH) Reveals Attendance at the Wall Street Reporter’s Next Super Stock Livestream Conference

RYAH Group is a digital healthcare analytics and technology company focused on developing tools that provide patients and doctors with the ability to accurately manage the intake in plant-based treatmentThe company recently revealed its participation at the Wall Street Reporter’s ‘Next Super Stock’ livestream conference held on September 23, 2021 RYAH Group (CSE: RYAH) is a leading digital health care analytics and technology company with…

Thursday Sep 30, 2021 - 10:58 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial

Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical studyThe study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients According to Tryp Chairman and CEO, the submission is the first of several IND filings the company intends to make in…

Tuesday Sep 28, 2021 - 12:32 pm

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) 10 Years in the Making: Innovation Leads to Multi (Pan)-Cancer Screening

After ten years, the concept of (multi)pan-cancer screening pioneered by AnPac Bio-Medical Science Co., Ltd. (AnPac Bio) has finally been accepted and the industry is shifting toward early screening technology that detects multiple cancers in blood at one time. In 2010, AnPac Bio proposed the theory of multi-cancer screening. At the time, the industry was divided over this innovative approach. The Company, however, persevered with…

Articles

Articles Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions